At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Nov 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 18 May 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 18 May 2001 No-Development-Reported for Cancer in USA (Unknown route)